Dialysis News and Research

Latest Dialysis News and Research

Janssen receives complete response letter for canagliflozin/metformin FDC therapy for type 2 diabetes

Janssen Research & Development, LLC (Janssen) today announced it has received from the U.S. Food and Drug Administration (FDA) a complete response letter regarding its New Drug Application (NDA) for a fixed-dose combination (FDC) of canagliflozin and immediate-release metformin to treat adults with type 2 diabetes.

16 Dec 2013

FDA accepts Shield Therapeutics' IND application to begin ST10 Phase 3 pivotal study for IDA treatment

Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces that the US Food and Drug Administration has accepted its Investigational New Drug application to initiate a Phase 3 pivotal study of ST10, its novel oral iron-replacement therapy, for the treatment of iron deficiency anaemia in pre-dialysis patients with chronic kidney disease. The Company plans to initiate the Phase 3 study in the US in H1 2014 and positive data would be the cornerstone of a subsequent NDA submission.

16 Dec 2013

Market research report on global and China insulin industry

As the third largest human health disease following neoplastic disease, cardiovascular and cerebrovascular diseases, the number of diabetic patients has continued growing from 246 million in 2007 to 382 million in 2013 at a compound annual growth rate of 7.6%.

12 Dec 2013

FDA grants indication for GORE VIABAHN Endoprosthesis to treat thrombotic occlusion

W. L. Gore & Associates today announced that the Food and Drug Administration has granted indication for the GORE VIABAHN Endoprosthesis to treat stenosis or thrombotic occlusion at the venous anastomosis of synthetic arteriovenous access grafts.

11 Dec 2013

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that results from two studies of REVLIMID (lenalidomide) combinations in patients with diffuse large B-cell lymphoma (DLBCL) were presented at the American Society of Hematology annual meeting in New Orleans, La.

11 Dec 2013

NOXXON Pharma reports interim data from two phase IIa studies of anti-CXCL12/SDF-1 Spiegelmer NOX-A12

NOXXON Pharma disclosed interim data from two independent clinical phase IIa studies of the anti-CXCL12/SDF-1 Spiegelmer olaptesed pegol (NOX-A12) at the 55th annual meeting of the American Society of Hematology in New Orleans, LA, USA from 7-10 December 2013.

9 Dec 2013

JCB Laboratories installs Lighthouse monitoring system to improve patient safety

JCB Laboratories, experts in sterile compounded solutions, has set the standard for environmental monitoring with the installation of a continuous cleanroom monitoring system from Lighthouse Worldwide Solutions. The pharmacy's latest improvement is a proactive approach to federal legislation that will bring new regulatory oversight to the compounding industry.

6 Dec 2013

PES' ESRD Prevention Program effectively identifies patients with early stage renal disease

Patient Engagement Systems, a nationally recognized leader in developing technology to identify, and monitor individuals with chronic kidney disease, today introduced the Patient Engagement Systems' ESRD Prevention Program which uses proprietary technology including automated physician-patient engagement, analytics, and decision support tools to identify patients with undiagnosed chronic kidney disease and tools to monitor them in order to prevent or delay the progression to ESRD.

3 Dec 2013

Siemens Healthcare to introduce new angiography system at RSNA 2013

At the 99th Scientific Assembly and Annual Meeting of the Radiological Society of North America, December 1-6 in Chicago, Siemens Healthcare (booth #1934, South Building/Lakeside Center at McCormick Place, Hall A) will introduce a new angiography system optimized for broad clinical utilization.

3 Dec 2013

Medicare reverses course and opts not to revamp dialysis payments

Federal officials announce that they will reduce what the program's payment by less than 1 percent over the next two years.

26 Nov 2013

First Edition: November 25, 2013

Today's headlines include reports about how political concerns and strategies are taking shape as a result of healthcare.gov's difficulties.

25 Nov 2013

ZOLL Medical announces establishment of ZOLL Foundation

ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today the establishment of the ZOLL Foundation, an independent entity organized for scientific and educational purposes.

16 Nov 2013

MGH investigators identify molecule that plays key role in the breakdown of kidney filter

One of the most devastating side effects of diabetes is kidney failure, and one of the earliest signs of kidney damage is a disruption of the organ's filtering capacity. Diabetes patients who develop kidney failure must go on dialysis, seriously limiting their quality of life and placing them at significantly increased risk of death. The incidence of kidney disease is increasing with rising rates of obesity-associated type 2 diabetes, but very little progress has been made towards protecting the kidney's filter barrier during the past 50 years.

16 Nov 2013

Satellite Healthcare, NKF partner to sponsor free Community Kidney Disease Symposium

Satellite Healthcare, one of the nation's first and leading not-for-profit providers of kidney dialysis services and a major sponsor of kidney research, is proud to announce that it has partnered with the National Kidney Foundation to sponsor NKF's free Community Kidney Disease Symposium this Saturday, November 16th in Stockton, California.

16 Nov 2013

OPKO Health completes patient enrollment in first phase 3 trial of Rayaldy for SHPT treatment

OPKO Health, Inc., has completed patient recruitment in the first phase 3 trial of Rayaldy to treat patients with secondary hyperparathyroidism, stage 3 or 4 chronic kidney disease and vitamin D insufficiency.

16 Nov 2013

FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

FibroGen, Inc. (FibroGen), today announced that data from a China-based Phase 2 study of roxadustat (FG-4592), a first-in-class oral compound in late stage development for the treatment of anemia associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD), were presented in an oral session at the 2013 American Society of Nephrology (ASN) Kidney Week in Atlanta, Georgia.

13 Nov 2013

Shield Therapeutics files IND application with FDA to initiate ST10 Phase 3 study

Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces that it has filed an investigational new drug application with the US Food and Drug Administration to initiate a Phase 3 pivotal study of ST10, its novel oral iron-replacement therapy, for the treatment of iron deficiency anaemia in pre-dialysis patients with chronic kidney disease.

12 Nov 2013

Dialysis News and Research

Latest Dialysis News and Research

Janssen receives complete response letter for canagliflozin/metformin FDC therapy for type 2 diabetes

FDA accepts Shield Therapeutics' IND application to begin ST10 Phase 3 pivotal study for IDA treatment

Market research report on global and China insulin industry

FDA grants indication for GORE VIABAHN Endoprosthesis to treat thrombotic occlusion

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

NOXXON Pharma reports interim data from two phase IIa studies of anti-CXCL12/SDF-1 Spiegelmer NOX-A12

JCB Laboratories installs Lighthouse monitoring system to improve patient safety

PES' ESRD Prevention Program effectively identifies patients with early stage renal disease

Siemens Healthcare to introduce new angiography system at RSNA 2013

Medicare reverses course and opts not to revamp dialysis payments

First Edition: November 25, 2013

ZOLL Medical announces establishment of ZOLL Foundation

MGH investigators identify molecule that plays key role in the breakdown of kidney filter

Satellite Healthcare, NKF partner to sponsor free Community Kidney Disease Symposium

OPKO Health completes patient enrollment in first phase 3 trial of Rayaldy for SHPT treatment

FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

Shield Therapeutics files IND application with FDA to initiate ST10 Phase 3 study

Results announced for Phase 3B/4 study of RAPAMUNE in kidney transplant patients

Many elderly patients who start dialysis after age 75 die within one year

Genetic factors put African Americans with CKD at greater risk for end-stage renal disease

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Dialysis News and Research

Latest Dialysis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in